Stock ADCT ADC THERAPEUTICS SA
Add to a list
To use this feature you must be a member
Log inSign up

All News ADC Therapeutics SA

Equities

ADCT

CH0499880968

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-22 pm EDT 		5-day change 1st Jan Change
3.67 USD -1.61% Intraday chart for ADC Therapeutics SA -11.14% +121.08%
May. 07 HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating MT
May. 06 Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
GL
ADC Therapeutics : RBC Capital Markets Global Healthcare Conference Presentation
PU
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
GL
HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating
MT
Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday
MT
ADC Therapeutics : 1Q 2024 Earnings Call
PU
ADC Therapeutics Launches $105 Million Offering; Shares Up 2% Pre-Bell
MT
Transcript : ADC Therapeutics SA, Q1 2024 Earnings Call, May 06, 2024
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
GL
ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial
MT
ADC Therapeutics SA Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GL
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
GL
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
CI
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
GL
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
GL
Transcript : ADC Therapeutics SA - Special Call
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed, Refractory B-cell Non-Hodgkin Lymphoma
AQ
Sector Update: Health Care Stocks Slump Late Afternoon
MT
ADC Therapeutics Shares Rise After Completion of Dose Escalation Part of Phase 1b Lymphoma Trial
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADCT Stock
  4. News ADC Therapeutics SA